Ecopipam
As of the edition of 20 October 2026, Ecopipam is a small molecule: in active development; acts on DRD1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2028
- Kind
- Small molecule
- Registered trials
- 21, 2 stopped early
- Disease areas
- Nervous system; Mental health; Inherited and neonatal; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| DRD1 | Dopamine receptor D1 | P21728 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 9 | 8 | 0 | 1 |
| Phase 2 | 7 | 7 | 0 | 0 |
| Phase 3 | 4 | 1 | 1 | 1 |
| All trials | 21 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Psyadon Pharma | Lead sponsor of trials | 2010 to now |
| Emalex Biosciences | Lead sponsor of trials |